Healthcare commercialisation group NetScientific announced on Monday that its portfolio company Wanda has achieved highly positive results in a study with congestive heart failure patients.
The study involved a system developed by Wanda which continuously assesses patients in real time and can detect adverse events up to a week before they happen, and resulted in a 46% reduction in hospital readmission rates for patients suffering from the heart condition.

AIM-traded company NetScientific holds a 62% stake on a fully diluted basis in Wanda.

Francois R. Martelet, NetScientific's chief executive and chairman of Wanda, said: "The data are impressive as patients with congestive heart failure typically have a very high re-admission rate. This demonstrates the invaluable potential Wanda's technology has in streamlining care and improving patient outcomes. We are entering a new digital era of healthcare in which we firmly believe Wanda can play a pivotal role."

The technology is intended to detect adverse effects up to a week in advance of their occurrence, which NetScientific said provides a significant and positive impact on patients' lives and provides a strong rationale for rolling out the system to more patients beyond the 576 involved in the study.

Wanda worked on the project and study with partner company Health Resource Solutions (HRS) who sourced the patient volunteers for the study.

As of 1039 BST, NetScientific's shares were up 10.34% at 48.00p.

Related share prices
NetScientific (NSCI) share price